<SEC-DOCUMENT>0001213900-25-104162.txt : 20251030
<SEC-HEADER>0001213900-25-104162.hdr.sgml : 20251030
<ACCEPTANCE-DATETIME>20251030161747
ACCESSION NUMBER:		0001213900-25-104162
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20251030
FILED AS OF DATE:		20251030
DATE AS OF CHANGE:		20251030

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NLS Pharmaceutics Ltd.
		CENTRAL INDEX KEY:			0001783036
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39957
		FILM NUMBER:		251435853

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		THE CIRCLE 6
		STREET 2:		8058
		CITY:			ZURICH
		PROVINCE COUNTRY:   	V8
		BUSINESS PHONE:		41-41-618-80-00

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		THE CIRCLE 6
		STREET 2:		8058
		CITY:			ZURICH
		PROVINCE COUNTRY:   	V8
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0263121-6k_nlspharma.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the Month of October 2025 (Report No. 9)
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-39957</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>NLS PHARMACEUTICS LTD.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Translation of registrant&rsquo;s name into
English)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The Circle 6</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>8058 Zurich, Switzerland</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of principal executive office)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#9746; Form 20-F &#9744; Form 40-F</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Completion of Merger
Transaction</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 30, 2025 (the
&ldquo;Closing Date&rdquo;), NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland (&ldquo;NLS&rdquo; or
the &ldquo;Company&rdquo;), completed the previously announced transaction with Kadimastem Ltd., an Israeli company
(&ldquo;Kadimastem&rdquo;), pursuant to the Agreement of Merger and Plan of Reorganization, dated as of November 4, 2024, and as
amended from time to time (the &ldquo;Merger Agreement&rdquo;), by and among the Company, Kadimastem and NLS Pharmaceutics (Israel)
Ltd., an Israeli company and a wholly owned subsidiary of the Company (the &ldquo;Merger&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the Merger,
the Registrant effected a 1-for-10 reverse stock split of the Company&rsquo;s common shares, preferred shares and preferred participation
certificates (the &ldquo;<U>Reverse Share Split</U>&rdquo;). The transactions contemplated by the Merger Agreement (including the Merger
and the Reverse Stock Split) were approved by the Company&rsquo;s shareholders at the extraordinary general meeting of shareholders held
on September 29, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of the closing of
the Merger, holders of common shares, preferred shares, preferred certificates and warrants of NLS at the time of the Merger also received
contingent value rights with respect to future net proceeds, if any, from the disposition of certain legacy assets of the Company (including
Mazindol ER, but excluding the DOXA platform).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, in connection with
the Merger, the Company changed its name to &ldquo;NewcelX Ltd.&rdquo; and the business conducted by the Company has been combined with
that of Kadimastem, creating an integrated biopharmaceutical company focused on the development of cell-based and small-molecule therapies
for neurodegenerative and metabolic diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
foregoing description of the Merger and the Merger Agreement is not complete and is subject to and qualified in its entirety by reference
to the Merger Agreement, a copy of which is attached as Exhibit 99.1 to the Report of Foreign Private Issuer on Form 6-K furnished to
the Securities and Exchange Commission on November 5, 2025, and which is incorporated herein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Press Release</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 30, 2025, the Company
issued a press release titled: &ldquo;NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger&rdquo; A copy of this press
release is furnished herewith as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT INDEX</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; width: 10%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit<BR>
Number</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 89%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description of Document</B></FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea026312101ex99-1_nlspharma.htm">Press
    release titled: &ldquo;NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger&rdquo;</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NLS Pharmaceutics Ltd.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 31%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: October 30, 2025</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Alexander C. Zwyer</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alexander C. Zwyer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea026312101ex99-1_nlspharma.htm
<DESCRIPTION>PRESS RELEASE TITLED: "NLS PHARMACEUTICS LTD. AND KADIMASTEM LTD. ANNOUNCE COMPLETION OF MERGER"
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="ex99-1_001.jpg" ALT="" STYLE="width: 340px; height: 67px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NLS Pharmaceutics Ltd. and Kadimastem Ltd.
Announce Completion of Merger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Combined Company Re-Named NewcelX Ltd., to Commence Trading on the
Nasdaq Capital Market<BR>
on October 31, 2025 under the Ticker Symbol &ldquo;NCEL&rdquo;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Zurich, Switzerland and Ness Ziona, Israel
October 30, 2025</B> &ndash; NewcelX Ltd. (&ldquo;NewCelX&rdquo; or the &ldquo;Company&rdquo;) completed the previously announced merger
transaction, pursuant to that certain Agreement of Merger and Plan of Reorganization, as amended from time to time, dated as of November
4, 2024 (the &ldquo;Merger Agreement&rdquo;), by and among NewCelX (f/k/a NLS Pharmaceutics Ltd. (&ldquo;NLS&rdquo;)), NLS Pharmaceutics
(Israel) Ltd. and Kadimastem Ltd. (&ldquo;Kadimastem&rdquo;), effective as of October 30, 2025 (the &ldquo;Merger&rdquo;). Upon completion
of the Merger, the Company changed its name to NewcelX Ltd. and, commencing on October 31, 2025, its ticker symbol on the Nasdaq Capital
Market will be &ldquo;NCEL.&rdquo; The traded warrants of the Company will be delisted from trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Merger Agreement, the holders
of Kadimastem ordinary shares outstanding immediately prior to the Merger received 0.706 NewCelX common shares in exchange for each Kadimastem
ordinary share in the Merger. The exchange ratio also reflects the 1-for-10 reverse share split effected by NewCelX in connection with
the Merger. Following completion of the Merger, NewCelX has approximately (i) 4,558,378 common shares, par value CHF 0.05 issued and outstanding,
(ii) 1,060,574 total outstanding common shares, par value CHF 0.05, issuable upon the exercise of pre-funded warrants issued as Merger
consideration, (iii) 13,778 preferred shares, par value CHF 0.05 issued and outstanding, and (iv) 58,320 preferred participation certificates,
par value CHF 0.05 issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of the closing of the Merger, holders
of common shares, preferred shares, preferred certificates and warrants of NLS at the time of the Merger also received contingent value
rights with respect to future net proceeds, if any, from the disposition of certain legacy assets of the Company (including Mazindol ER,
but excluding the DOXA platform).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;This merger unites years of pioneering
science in cell therapy and drug discovery under one global platform,&rdquo; said <B>Prof. Michel Revel, Chief Scientific Officer of NewCelX</B>.
&ldquo;NewCelX represents the next step in realizing the promise of regenerative medicine for patients living with amyotrophic lateral
sclerosis&nbsp; (&ldquo;ALS&rdquo;), diabetes, and other neurodegenerative diseases.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ronen Twito, Executive Chairman and Chief Executive
Officer of NewCelX </B>said, &ldquo;With the launch of NewCelX, we have brought together exceptional science and a global leadership team
with the potential to change lives. The completion of the merger and the commencement of trading on Nasdaq mark a significant milestone
that reflects the trust and confidence of our shareholders and investors, and I am deeply grateful for their support as we take this next
step forward together. We are now preparing to initiate our Phase 2a clinical trial of AstroRx&trade; in ALS and to advance the development
of IsletRx&trade; for the treatment of Type 1 diabetes without the need for lifelong immunosuppression.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NewCelX is headquartered in Zurich, Switzerland,
and led by the leadership of NLS and Kadimastem, including led by Ronen Twito, as Executive Chairman and Chief Executive Officer. The
leadership team also includes Prof. Michel Revel, Director and Chief Scientific Officer; Alexander Zwyer, Director; Kfir Molakandov, PhD,
Vice President of R&amp;D; Prof. Ariel Revel, MD, Medical Director; and Eric Konofal, MD, PhD, Head of the DOXA Program. The board of
directors of NewCelX includes Ronen Twito, Prof. Michel Revel, Alexander Zwyer, Olivier Samuel, Eran Iohan, Liora Oren, and Tammy Galili.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About NewCelX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NewcelX Ltd. (Nasdaq: NCEL) is a biotechnology company developing transformative
cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company&rsquo;s integrated platform combines
advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic
Lateral Sclerosis (ALS) and Type 1 Diabetes. NewCelX is headquartered in Zurich, Switzerland, with research and development operations
in Ness Ziona, Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains expressed or implied
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable securities
laws. For example, NewCelX is using forward-looking statements when it discusses the expected start of trading date for NewCelX on Nasdaq,
its belief that the merger unites pioneering science in cell therapy and drug discovery under one global platform, its expectation that
NewCelX will realize the promise of regenerative medicine for patients with ALS, diabetes, and other neurodegenerative diseases, its belief
that the formation of NewCelX creates a biotechnology company with the potential to change lives, its confidence in the trust and support
of its shareholders and investors, its intention to advance transformative therapies in neurodegenerative and metabolic diseases, and
its plans to initiate a Phase 2a clinical trial of AstroRx&trade; in ALS and to advance the development of IsletRx&trade; for the treatment
of Type 1 diabetes without the need for lifelong immunosuppression. These forward-looking statements and their implications are based
on the current expectations of the management of NewCelX and are subject to a number of factors and uncertainties that could cause actual
results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause
actual results to differ materially from those described in the forward-looking statements: unexpected costs, charges or expenses resulting
from the Merger and potential adverse reactions or changes to business relationships resulting from the completion of the Merger; changes
in technology and market requirements; NewCelX may encounter delays or obstacles in launching and/or successfully completing its clinical
trials; NewCelX&rsquo;s products may not be approved by regulatory agencies; its technologies may not be validated as they progress and
NewCelX&rsquo;s methods may not be accepted by the scientific community; NewCelX may be unable to retain or attract key employees whose
knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with the products being advanced
by NewCelX; its products may wind up being more expensive than anticipated; results in the laboratory may not translate to equally good
results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; NewCelX&rsquo;s
patents may not be sufficient; its products may harm recipients; changes in legislation may adversely impact NewCelX; NewCelX may be unable
to timely develop and introduce new technologies, products and applications; and NewCelX may experience loss of market share and pressure
on pricing resulting from competition, which could cause the actual results or performance of candidate products to differ materially
from those contemplated in such forward-looking statements. Except as otherwise required by law, NewCelX does not undertake any obligation
to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect
the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting NewCelX is contained under
the heading &ldquo;Risk Factors&rdquo; in NLS&rsquo;s annual report on Form 20-F for the year ended December 31, 2024, filed with the
Securities and Exchange Commission (&ldquo;SEC&rdquo;), which is available on the SEC&rsquo;s website, www.sec.gov, and in subsequent
filings made by NLS with the SEC, including under the heading &ldquo;Risk Factors&rdquo; in NLS&rsquo;s proxy statement/prospectus, filed
with the SEC on September 10, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NewCelX Investor &amp; Media Contacts:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sarah Bazak, Investors Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">sarahb@newcelx.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">www.newcelx.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Social Media: LinkedIn,
X, Facebook, Instagram&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "N W,# 2(  A$! Q$!_\0
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M/L*N,'+8#Z<HKY TSXO>-M,N3-_;4MUD8V70\Q?RKWCX<_%K3O&JBQO ECK
M_P"6);Y9AZH3U/J*<J;CJ!Z/11168!1110 4444 %%>+?$SXN:UX.\7-I-C;
M6LD(@23=(#G)S_A7'?\ #0WB;_GQL?\ ODUHJ<FK@?35%?,O_#0WB;_GQL?^
M^37K/PG\<ZCXYTF^NM1AAB>WE5%$0X(()HE3E%78'H-%%%9@%%>5_%KXDZKX
M$OM,ATZWMY5NHW=S*#P00./SKSG_ (:&\3?\^-C_ -\FM%3DU= ?35%?,O\
MPT-XF_Y\;'_ODT?\-#>)O^?&Q_[Y-/V4@/IJBOF7_AH;Q-_SXV/_ 'R:/^&A
MO$W_ #XV/_?)H]E(#Z:HKYE_X:&\3?\ /C8_]\FC_AH;Q-_SXV/_ 'R:/92
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M_P (_B#J?CR/5VU&""+[&80GE \[]^<_]\BDZ<DKL#TNBBBLP"BBB@ HHHH
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M; %>_P#[-7^I\2_[UM_*6O *]_\ V:O]3XE_WK;^4M15^%@>\T445Q@%%%%
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MPI#P)_T"Y?\ P)?_ !KY:T/4$TK7K#4)(VD2VN$E9%."P4@X%>^_\-(:/_T
M+[_OZE8U%)OW0.H_X4AX$_Z!<O\ X$O_ (T?\*0\"?\ 0+E_\"7_ ,:Y?_AI
M#1_^@!??]_4H_P"&D-'_ .@!??\ ?U*SY:@'4?\ "D/ G_0+E_\  E_\:/\
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M ,#!_P#$4O9R[ >Z45X7_P -)VG_ $+,_P#X&#_XBC_AI.T_Z%F?_P #!_\
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M,_\ X&#_ .(H_P"&D[3_ *%F?_P,'_Q%'LY@>Z45X7_PTG:?]"S/_P"!@_\
MB*/^&D[3_H69_P#P,'_Q%'LY=@/=**\@\._&^X\5:O%IFE>$9Y9Y#R3> *B]
MV8[. *]?J7%K< HHHJ0/A[Q7_P CCKG_ &$)_P#T8U9%:_BO_D<=<_["$_\
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M8VL8CM[>-8HU'90,"L*LK*P%BBBBN8 HHHH *^=OC_X+%G?0^*K*+$5RPBO
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MOW">_4]O6M;X4_!K[8L&O^)X66 X>VLF&"_<,_MZ#\Z^A$18T5$4*JC 4#
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M HHHJ0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HK$U'QAX=TB\:SU'6;*UN5 +12S!6 /(XIMGXU\,:A<+!:Z_ILLSG"QB
MY3<Q] ,\T ;M%%% !15#5=:TS0[=+C5+Z"SA=MBO,X4%NN.?H:R?^%A^#_\
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M%-CD2:))(V#(X#*PZ$&G4 %%94'B71;K6)-)@U.UDU",LKVRR NI'4$>U:M
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M>AZ9IB/<:**0D*"20 .232&>._'75'NTT7PE:G=/J$XEE5!E@@.U3CT)W?\
M?-8GPX1OA[\7]2\(S3%[:\C18Y&3!D<+N4C\&<'W%8%]XCU76?C->>(=+T2\
MUF/2Y?+@A@5I @7*@Y4'@D,P^M5?'OB+Q)>^)=*\4W_AB_T26SVQ+(Z2('PQ
M8#+ <\M^%,1]3U%<V\=W:RVTR[HI4,;KZJ1@BJ^D:C%J^CV>HPE3'<PK*-IS
MC(R1GVZ5=I#/&?B5\,_"F@_#W5M2T[31%=P+&8WW$XS(H/Z$U+\/OACX3UOP
M%I&HW^F"6ZGA+2/O(R=Q%=1\8O\ DE&N_P"Y%_Z-2I_A1_R3#0?^N!_]"-,#
ML(HUAB2)!A$4*H] *=112 ^>O"7_ "<QJO\ U\77_H+5]"U\]>$O^3F-5_Z^
M+K_T%J^A:8@KY>^*VEWFJ?%_64L 3/;VJ7.!UQ'"K''O@5]0UXI&H;]J2Y5A
MD&SP1_V[B@9L6'B\>-O@CJMVY!OX;*2"[7I^\"]?^!#!_&J/[.G_ ")>I_\
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>*** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
